Graziano Seghezzi brings nearly a decade of European venture capital investment experience to Sofinnova Partners, where he has been a partner focused on life sciences investment since joining the firm in 2006.
Graziano has been instrumental in targeting, investing in, and nurturing the growth of a number of Sofinnova Partners’ portfolio companies, including: Creabilis Therapeutics (Italy), a specialty dermatology company developing products in multiple clinical areas such as psoriasis and atopic dermatitis; Crescendo Biologics (UK), a seed-stage company targeting the application of highly innovative antibody fragment technologies to the development of new therapeutics; GlycoVaxyn (Switzerland), a biotechnology company dedicated to the development of novel vaccines; and Omthera (USA), specialized in cardiovascular disorders with a best-in-class
omega-3 drug. Graziano is a board member of each company.
Prior to joining Sofinnova Partners’ Paris-based team, Graziano was principal at Index Ventures in Geneva, Switzerland, where he invested in biotechnology and biopharmaceuticals companies. Before this, he worked for Sofinnova Partners, identifying new investment opportunities in Italian pharmaceutical and medical device companies out of Milan, Italy. Graziano began his career as a biomedical researcher at New York University’s School of Medicine, where he gained five years of hands-on experience studying the molecular mechanism of angiogenesis in oncology and cardiovascular diseases.
Graziano has a degree in genetics and microbiology from the University of Pavia (Italy) and an MBA from the RSM, Erasmus University (Netherlands).